Kroatië - Kroatisch - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dechra regulatory b.v., handelsweg 25, 5531 ae bladel, nizozemska - tiamulinhidrogenfumarat - otopina za primjenu u pitkoj vodi - antimikrobni lijekovi za sustavne infekcije - svinja, kokoši (pilenke, rasplodne kokoši, nesilice konzumnih jajaj), purana (rasplodni purani, nesilice konzumnih jaja)

Kroatië - Kroatisch - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dechra regulatory b.v., handelsweg 25, 5531 ae bladel, nizozemska - tiamulinhidrogenfumarat - otopina za primjenu u pitkoj vodi - antimikrobni lijekovi za sustavne infekcije - svinja, kokoši (pilenke, rasplodne kokoši, nesilice konzumnih jajaj), purana (rasplodni purani, nesilice konzumnih jaja)

Kroatië - Kroatisch - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dechra regulatory b.v., handelsweg 25, 5531 ae bladel, nizozemska - pimobendan - oralna otopina - srčani stimulatori, isključujući srčane glikozide, inhibitori fosfodiesteraza - pasa

Europese Unie - Kroatisch - EMA (European Medicines Agency)

dechra regulatory b.v. - tulathromycin - antibakterijska sredstva za sistemsku uporabu - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. prisutnost bolesti u stadu treba biti uspostavljena prije metafilaktičkog liječenja. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. prisutnost bolesti u stadu treba biti uspostavljena prije metafilaktičkog liječenja. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovce: liječenje ranih stadija infektivnog pododermitisa (trbuha nogu) povezanih s virulentnim dichelobacter nodosusom koji zahtijeva sustavno liječenje.

Europese Unie - Kroatisch - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Europese Unie - Kroatisch - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Europese Unie - Kroatisch - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

medic d.o.o., zagreb - reguliranje protoka cerebrospinalne tekućine i odvođenje cerebrospinalne tekućine

Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

sonimed d.o.o., zagreb - regulacija tjelesne temperature, hlađenje i grijanje tijela

Kroatië - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -